FDA approves Pfizer maternal vaccine for infants

CFOTO | Future Publishing | Getty Images

The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization amongst babies within the U.S.

Pfizer’s RSV shot is already approved and available within the U.S. for older adults.

It’s now the second treatment approved by the FDA to prevent RSV in infants and the primary vaccine. It uses maternal immunization, which refers to vaccinating pregnant moms in order that they can pass protective antibodies to their fetuses.

Pending a advice by the Centers for Disease Control and Prevention, Pfizer hopes the vaccine can be available to the general public by the tip of October or the start of November, which marks the start of RSV season, in line with Alejandra Gurtman, the corporate’s senior vp of clinical research and development for vaccines. 

“Once you think globally, this vaccine could potentially have an enormous public health impact,” Gurtman told CNBC. “After 50 years of trying to search out a way where we will protect babies through the first three or especially six months of life, this vaccine is something I’m very pleased with.” 

Dr. Peter Marks, the FDA’s vaccine head, added in a release that the approval provides another choice for health care providers and pregnant individuals to “protect infants from this potentially life-threatening disease.”

The FDA in mid-July approved an RSV monoclonal antibody from Sanofi and AstraZeneca that’s directly administered to infants. The CDC really useful that drug to all infants under eight months of age and a few older babies.  

The agency’s panel of advisors is anticipated to meet and consider a advice for Pfizer’s vaccine in October, nevertheless it’s unclear how it’ll compare to the rules set for the primary treatment since it is not given to infants.

Pfizer’s jab is specifically administered to expectant moms within the late second or third trimester of their pregnancy. The one-dose vaccine triggers antibodies which can be passed to the fetus, which provides it with protection against RSV from birth through the primary six months of life.

RSV normally causes mild, cold-like symptoms. But younger children and older adults are particularly vulnerable to more severe RSV infections. 

Annually, the virus kills a number of hundred children younger than 5, and 6,000 to 10,000 seniors, in line with the CDC. 

The shot would help the U.S. combat the upcoming RSV season because it comes off an unusually severe yr. 

Cases of the virus in children and older adults overwhelmed hospitals across the country, largely because the general public stopped practicing Covid pandemic health measures that had helped contain the spread of RSV. 

Safety and efficacy data

The FDA’s approval of Pfizer’s vaccine was based on data from a phase three trial, which found that the shot was nearly 82% effective at stopping severe disease from RSV in newborns through the first 90 days of life. 

The vaccine was also about 70% effective through the first six months of the newborn’s life.

In May, the FDA’s panel of advisors unanimously said the information showed Pfizer’s vaccine was effective. 

Respiratory syncytial virus – viral vaccine under research

Hailshadow | Istock | Getty Images

But some advisors expressed concerns about safety. 

A rather higher variety of premature births occurred amongst moms who took the shot in comparison with those that received a placebo: 5.7% versus 4.7%, respectively. 

The FDA, following the approval Monday, said the available data “are insufficient to determine or exclude a causal relationship between preterm birth” and Pfizer’s vaccine.

Pfizer’s Gurtman also said the difference in premature birth rates was “not statistically significant.”

She noted that almost all premature births occurred 30 days after vaccination, which implies “a really close causal relationship between the vaccine and preterm birth couldn’t be identified.” 

“We couldn’t find any reason why this really happened,” Gurtman said. 

She added that some upper middle-income countries, including the U.S. and Japan, didn’t see a better rate of premature births in moms who took the vaccine. 

Still, Gurtman said Pfizer goes to look at the risks in a post-marketing study on the vaccine. “Post-marketing” refers to research conducted on a product after it receives FDA approval.

The corporate’s post-marketing can even involve evaluating any pregnancy-related complications following vaccination, she added. That features eclampsia, which refers to seizures that develop while pregnant or shortly after birth. 

Pfizer will launch a pregnancy registry that may allow women and obstetricians to call and report any hostile events after receiving the vaccine, in line with Gurtman.